InventisBio (SHA:688382) resubmitted its application for a secondary offering on the Hong Kong Stock Exchange, according to a Monday disclosure to the Shanghai bourse.
The biopharmaceutical company's offering application filed in January had already lapsed, the Hong Kong bourse said.
Zelgen plans to use proceeds from its planned offering to develop its core products, preclinical product candidates, antibody-drug conjugate technology platform, and for working capital.
Company shares slipped 3% during the midday break on Monday.